Lu 177 ethylenedicysteine amifostine - CellPoint
Alternative Names: (177)Lu ethylenedicysteine amifostine; 177Lu ethylenedicysteine amifostine; 177Lu-EC-Amifostine; Ethylenedicysteine amifostine-Lutetium-177; Lutetium 177 ethylenedicysteine amifostineLatest Information Update: 30 Mar 2020
At a glance
- Originator CellPoint
- Class Chemoprotectants; Diagnostic conjugates; Organometallic compounds; Organothiophosphorus compounds; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Oxygen radical scavengers; Positron-emission tomography enhancers; Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 24 Mar 2020 Early research in COVID-2019 infections (Diagnosis) in USA (Parenteral) before March 2020
- 24 Mar 2020 Early research in COVID-2019 infections in USA (Parenteral) before March 2020
Development Overview
Introduction
Lutetium labelled ethylenedicysteine (EC) amifostine (177Lu-EC-Amifostine), is a theranostic agent, being developed by Cellpoint for detection and treatment of COVID-2019 infections, by using EC drug conjugate platform. The company has in-licensed the EC platform from the M.D. Anderson Cancer Center, wherein tissue specific ligands or pharmaceutical compounds are linked to cold metals or radioisotopes. Upon targeted delivery, EC-Amifostine which is an organic thiophosphate with oxygen scavenging activity, metabolised by alkaline phosphatase (ALP) present on neutrophil surface in the lungs to an active thiol analog, which scavenge free-radicals and stabilise DNA to protect the infected organs. 177Lu-EC-Amifostine can be detected using both PET and SPECT for imaging to assess location and degree of viral infection and associated damage as well as follow-up confirmatory imaging to determine post treatment resolution. Amifostine was originally developed by the Southern Research Institute in Birmingham, Alabama, USA. Early-stage development is underway in the US.
Company Agreements
In June 2005, CellPoint obtained the worldwide patent and technology license to oligosaccharide conjugates for dual imaging and radio/chemotherapy developed at the University of Texas M. D. Anderson Cancer Center. The imaging agents will be used in SPECT/CT and PET/CT. This dual agent technology is also facilitating the development of targeted radio/chemotherapeutic agents. [1]
Key Development Milestones
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Chemoprotectants, Diagnostic conjugates, Organometallic compounds, Organothiophosphorus compounds, Radiopharmaceutical diagnostics, Small molecules
- Mechanism of Action Oxygen radical scavengers; Positron-emission tomography enhancers; Single-photon emission-computed tomography enhancers
-
WHO ATC code
V09E-X (Other respiratory system diagnostic radiopharmaceuticals)
V09H-X (Other diagnostic radiopharmaceuticals for inflammation and infection detection)
V10A (Antiinflammatory Agents)
V10X-X (Various therapeutic radiopharmaceuticals)
-
EPhMRA code
T1G (Radiodiagnostic Agents)
V3C (Radiopharmaceuticals)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | Research | USA | Parenteral / unspecified | CellPoint | 24 Mar 2020 |
| COVID 2019 infections | - | Diagnosis | Research | USA | Parenteral / unspecified | CellPoint | 24 Mar 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| CellPoint | Originator | USA |
| CellPoint | Owner | USA |
| University of Texas M. D. Anderson Cancer Center | Technology Provider | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 24 Mar 2020 | Phase Change | Early research in COVID-2019 infections (Diagnosis) in USA (Parenteral) before March 2020 Updated 30 Mar 2020 |
| 24 Mar 2020 | Phase Change | Early research in COVID-2019 infections in USA (Parenteral) before March 2020 Updated 30 Mar 2020 |
| 03 Jun 2005 | Licensing Status | Cellpoint in-licenses Oligosaccharide Conjugates for dual imaging and radio/chemotherapy from University of Texas M. D. Anderson Cancer Center [1] Updated 30 Mar 2020 |
References
-
Cell Point acquires Oligosaccharide Conjugate License.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG